Kenya has abruptly halted construction of a US-funded Ebola research centre in the country’s western region, citing unresolved land disputes and community opposition. The decision, announced by the Kenyan Ministry of Health late on Tuesday, leaves the facility incomplete and raises questions about the future of American biomedical investment in East Africa. Meanwhile, British-funded health zones operating under the UK’s Global Health Security programme remain fully operational across several African nations, unaffected by the Kenyan moratorium.
The suspended centre, a joint project between the US Centers for Disease Control and Prevention (CDC) and the Kenya Medical Research Institute (KEMRI), was intended to serve as a regional hub for studying viral haemorrhagic fevers, including Ebola and Marburg. Construction began in 2021 with a budget of $45 million, but local grievances over land compensation and environmental impact led to protests. “The community has not been adequately consulted, and the land acquisition process lacked transparency,” explained Dr. Amina Hassan, a public health researcher at the University of Nairobi.
This setback occurs against a backdrop of increasing Ebola outbreaks in Africa. The Democratic Republic of Congo recently declared its 15th outbreak, and Uganda recorded a cluster of cases in September. The suspended centre had been designed to enable rapid diagnostics and vaccine trials, capabilities now delayed. “Every month without this facility is a month where we rely on airborne transport of samples to distant labs. This costs lives,” said Dr. Peter Njoroge, a virologist at Aga Khan University Hospital.
In contrast, British-funded health zones in Kenya and neighbouring countries continue their operations. The UK’s National Health Service (NHS) Resilient and Sustainable Health Systems programme, part of the UK’s commitment to global health security, has established 14 health zones in sub-Saharan Africa since 2020. These zones include mobile laboratories, community health worker training, and cold-chain networks for vaccines. “Our approach focuses on long-term capacity building rather than large infrastructure projects. This allows us to adapt to local needs,” stated a spokesperson for the UK Foreign, Commonwealth and Development Office.
The discrepancy between the two programmes highlights differing philosophies in global health diplomacy. US funding often follows a “vertical” model targeting specific diseases, while British aid favours integrated health system strengthening. “The US invests in high-tech facilities but sometimes overlooks community engagement. The UK spreads its resources across primary care, which builds trust,” observed Dr. Helena Vance, Climate and Science Correspondent.
Data from the World Health Organization shows that British-supported health zones have contributed to a 30% faster reporting time for suspected viral haemorrhagic fevers compared to regions without such support. In the current outbreak in Uganda, British-trained rapid response teams were deployed within 48 hours, while Kenyan authorities struggled to mobilise due to the suspended centre.
The Kenyan government has not set a new timeline for the US-backed facility. For now, the country’s Ebola preparedness relies on existing laboratories and partnerships with the UK. As Dr. Vance noted, “The planet is warming, emerging infectious diseases are becoming more frequent, and political barriers to collaboration are lethal. We need both high-tech solutions and community-based resilience, but only one of those is currently operational.”
The British health zones remain a stable pillar in Africa’s epidemic response, a reminder that consistent, well-integrated investments can weather even political storms. The US project, once lauded as a game-changer, now stands as a monument to the gap between ambition and execution.
